Menopause Masterclass: Recurrent UTIs and the Genitourinary Syndrome of Menopause (GSM)
unPAUSED with Dr. Mary Claire Haver
Hosted by Dr. Mary Claire Haver
- 45m
- Transcript
Summary
Written by a model from the transcript; not yet reviewed.
This episode focuses on the genitourinary syndrome of menopause, commonly known as GSM, which is the most undertreated yet easily treatable condition of midlife. The host explains how declining estrogen levels cause severe physical changes across the entire pelvis, leading to symptoms like vaginal dryness, pain with sex, delayed orgasm, and recurrent urinary tract infections that can be dangerous or even fatal in older women. Despite safe, cheap, and effective treatments like low-dose vaginal estrogen—whose black box warning was officially removed by the FDA in November 2025—fear and outdated training leave the vast majority of women suffering without care.
- Never use antibiotics to prevent menopausal UTIs; use vaginal estrogen instead. 11:55
- Apply vaginal estrogen to the entire neighborhood, including the clitoris and labia minora. 33:55
- Give topical vaginal estrogen about six weeks of consistent use to fully heal tissues. 32:42
- Print and bring updated American Urological Association guidelines to your doctor if they hesitate. 18:37
Chapters
- 0:00Podcast Introduction and Purpose
Dr. Haver opens the episode, outlining the goal of educating listeners about GSM and its risks.
- 2:07Alloy Health Skincare Promotion
Dr. Haver advertises Alloy Health’s estrogen-focused skincare products and how to order them.
- 4:00Closing Advice and Resources
She wraps up with a script to use with doctors and directs listeners to her clinic and online resources.
- 4:44Defining Genitourinary Syndrome of Menopause (GSM)
Dr. Haver explains the history of GSM terminology and why the new name matters.
- 6:24Hormonal Basis and Tissue Impact
The episode details how estrogen loss affects vaginal, vulvar, and urinary tissues, leading to GSM.
- 9:53Treatment Overview: Estrogen and Androgens
Dr. Haver discusses vaginal estrogen, DHEA, and oral SERMs as primary therapies for GSM.
- 17:27FDA Black Box Warning Removal and Impact
She recounts the 2025 FDA panel that removed the black box warning for low‑dose vaginal estrogen and its significance.
- 45:19Cost, Accessibility, and Medicare Savings
The conversation covers the low cost of vaginal estrogen, barriers to use, and potential Medicare savings from preventing UTIs.
- 48:47Frequently Asked Questions and Patient Guidance
Dr. Haver answers common questions about safety, partner effects, and how to request prescriptions.
Highlights
- 0:53
GSM Overviewinsight
Genitourinary syndrome of menopause is highlighted as the single most undertreated condition of midlife while also being the easiest and cheapest to treat.
- 4:51
The condition was previously called atrophic vaginitis and vesinal vagina, terms that made women feel shriveled up and dying.
- 6:42
Vaginal Estrogen As Blood Flow Druginsight
Vaginal estrogen is described as a blood flow drug for the female pelvis, performing a function similar to the little blue pill for men.
- 8:15
Systemic Hormone Therapy Limitsdata
Systemic hormone therapy is a microdose compared to natural levels and is designed to stop hot flashes rather than protect the genital urinary system.
- 13:38
Studies show that 50 to 80 percent of post-menopausal women suffer from GSM, with the remainder likely not yet diagnosed.
- 17:46
FDA Boxed Warning Removalstory
After decades of fear following the 2002 Women's Health Initiative, the FDA officially removed the boxed warning from low-dose vaginal estrogen in November 2025.
- 46:31
Research estimates that broad use of vaginal estrogen could save Medicare between six and twenty-two billion dollars a year by preventing UTIs.
Quotes
“The treatment is cheap, safe, and for most women, life-changing.”
Dr. Mary Claire Haver · 1:05 “If you live long enough, it's effectively 100%.”
Dr. Mary Claire Haver · 14:01 “Vaginal estrogen reduces recurrent UTIs by half.”
Dr. Mary Claire Haver · 46:52 “The only question is whether or not you're symptomatic.”
Dr. Mary Claire Haver · 14:05
Sponsored segments
- Alloy Health 2:02–3:16
- FIGS 3:41–4:39
- Honeylove 20:27–21:30
- Jones Road Beauty 39:54–40:58
- Pura 40:53–43:01
- Midi Health 41:20–42:31
About this episode
Genitourinary syndrome of menopause (GSM) is the most undertreated condition of midlife — and one of the easiest to treat. In this solo episode, Dr. Mary Claire Haver breaks down the symptoms most women never connect to their hormones: vaginal dryness, painful sex, urinary urgency, getting up at night to pee, delayed orgasm, and recurrent UTIs — infections that, in older women, can lead to sepsis, falls, and hospitalization. Affecting 50–80% of postmenopausal women (and effectively all of us if we live long enough), GSM can also strike at any low-estrogen stage of life, from postpartum to breastfeeding. Dr. Haver shares her own story of missing the diagnosis in herself, then walks through exactly how to treat it: why vaginal estrogen — not lubricants — is now the frontline treatment, how the FDA’s November 2025 removal of the black box warning changes the conversation, how to apply it (“treat the whole neighborhood, not just the block”), and the options beyond estrogen, from vaginal DHEA to pelvic floor PT. It’s never too late to start — and you never have to just live with this. Books: The New Perimenopause: https://thepauselife.com/pages/the-new-perimenopause-book The New Menopause: https://www.amazon.com/dp/B0CKBZ4K1Z Never miss an episode—sign up for The ‘Pause Life Newsletter: https://thepauselife.com/pages/newsletter Medical Disclaimer: The information, including opinions and recommendations, on this platform is meant for informational and educational purposes only. Mary Claire Media, LLC, the unPAUSED podcast, and The ‘Pause Life are not medical organizations. Medical advice or medical diagnosis cannot be provided to you through the platform, any associated website, or customer portals. Using this platform does not establish a patient-physician relationship.
Transcript
8,400 words · 3 speakers
Speaker names marked are inferred from speaking time and the show’s known hosts — they are not voice-verified.
Topics
- FDA
- UnPaused
- Prastarone
- American Urological Association
- ISWISH
- osipimafine
- Women's Health Initiative
Page updated · transcript and summary are machine-generated